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Abstract
Ageing is associated with declines in many physiological parameters, including multiple immune
system functions. The rate of acceleration of the frequency of death due to cardiovascular disease
or cancer seems to increase with age from middle age up to around 80 years, plateauing thereafter.
Mortality due to infectious disease, however, does not plateau, but continues to accelerate
indefinitely. The elderly commonly possess oligoclonal expansions of T cells, especially of CD8 cells,
which, surprisingly, are often associated with cytomegalovirus (CMV) seropositivity. This in turn is
associated with many of the same phenotypic and functional alterations to T cell immunity that have
been suggested as biomarkers of immune system aging. Thus, the manner in which CMV and the
host immune system interact is critical in determining the "age" of specific immunity. We may
therefore consider immunosenescence in some respects as an infectious state. This implies that
interventions aimed at the pathogen may improve the organ system affected. Hence, CMV-directed
anti-virals or vaccination may have beneficial effects on immunity in later life.
Background
Ageing is associated with multiple immune system dys-
functions [1]. An important current direction for immu-
nosenescence research is towards assessing the clinical
impact of age-associated modifications of immunity and
modulating them. Infectious disease is increased in fre-
quency and severity in the elderly, implying that age-asso-
ciated decreasing immunity results in increased incidence
in those diseases which the immune system has evolved to
combat. It is well-established that the incidence and case
fatality-rate of infections like tuberculosis, pneumonia,
bacteraemia and cholecystitis are increased in elderly peo-
ple [2]. In a study of Japanese women, the annual death
rate from pneumonia continued to accelerate with age,
whereas stroke, lung and stomach cancer rates plateaued
[3].
Increased infections in older people can be explained by
several interacting factors. First, decreased immune func-
tion may be due to hidden diseases and/or medication
and/or malnutrition. Ageing per se is associated to loss of
integrity of physical barriers along with decreased hygiene
that lead to an increased susceptibility to infection. Sec-
ondly, to decreased immunocompetence towards certain
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and housing conditions (eg. nursing houses, geriatric
wards and houses for the elderly) may also contribute to
increased infections in the elderly particularly due to
nosocomial infection [2].
Senescence of the clonotypic immune system is thought
to be principally the result of a non-adapted T cell
response to stimulation. Many age-associated changes in
T cell phenotype and function are caused by the process of
senescence [4]. Lifelong and chronic antigenic load may
represent the major driving force for immunosenescence,
which impacts on human lifespan by reducing the
number of virgin antigen-non experienced T cells, and
results in their replacement by expanded clones of anti-
gen-experienced effector and memory T cells which dis-
play a late differentiation phenotype. Gradually, the T cell
population shifts to a lower ratio of naïve cells to memory
cells, the thymus releases fewer naïve T cells with age and
those T cells remaining, especially the CD8+ subset, also
show increased oligoclonality with age. Thus, the reper-
toire of cells available to respond to antigenic challenge
from previously unencountered pathogens shrinks. In
addition, older organisms often are overrun by memory
cells that carry a single type of T cell receptor, i.e. the
clonal expansion referred to above. Thus, the memory
cells from old individuals might recognize a limited set of
antigens despite being plentiful in number, and in addi-
tion, are likely to show various degrees of dysfunctional-
ity. Many of the clonal expansions filling the individual's
immune system seem to result from previous infections
by persistent viruses, especially CMV, but also, to a lesser
extent, EBV and possibly other herpesviruses. A high
number of CD8+ cells are found to be specific for a single
epitope of cytomegalovirus: in some individuals up to a
quarter of circulating CD8 cells carry receptors for a single
CMV epitope [5-7]. T cells subsets commonly carry the
CD28 surface molecule, which co-stimulates the cells to
divide when an antigen is presented by the APC. However,
old memory cells, i.e. CD8 cells that have encountered the
antigen a long time ago and have been chronically stimu-
lated over time, tend to lose CD28 and, as a result, multi-
ply less robustly when exposed to antigens than do
younger cells (Table 1). The hypothesis derived from the
above findings is that T cell immunosenescence and, pos-
sibly, mortality and morbidity will occur earlier in people
that have been exposed to an antigenic overload (due to
chronic infections). The opposite will apply both in peo-
ple exposed to a lower antigenic load and in people
equipped with an immunogenetic background able to
more efficiently deal with these types of infections. This
means that the ability of our immune system is progres-
sively worn out by the requirement for constant immuno-
surveillance against persistent antigen sources. In
developed countries, improved hygienic conditions and
the consequently lower level of bacterial contamination
of food and water could have reduced the antigenic over-
load preserving the immune system from rapid exhaus-
tion and helping a large number of individuals to extend
their longevity [4,8-11].
Octo/nona longitudinal studies
The use of a longitudinal design in ageing research is
highly desirable for conducting population-based studies
by advantages in identifying age-related alterations and
the detection of intra-individual changes [12]. Although
the longitudinal design is a superior alternative to the
cross-sectional method for conducting ageing research it
has seldom been employed because of extensive costs,
need of careful coordination and long duration. Particu-
larly rare are longitudinal studies on individuals over 85
years of age, the group of people deliberately focused on
in the Swedish OCTO/NONA longitudinal studies [6].
These studies initially examined age-related changes in a
limited number of immune parameters but are now per-
forming more sophisticated immunological assessments.
There are some parameters which are important for suc-
cessful ageing, which can only be revealed by such longi-
tudinal studies. At first, a cluster of immunological
parameters which define an immunological risk pheno-
type predicting 2-year mortality in very old individuals
was established in the earlier OCTO study [13]. The term
"Immunological Risk Profile" (IRP), took into considera-
tion elements like an inverted CD4:8 ratio, poor T cell
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production, increased numbers of CD8-positive CD28-
negative cells, decreased B cell count, and later, CMV sero-
positivity, which also seems to play an important role in
determining the IRP (Table 2) [6,7].
CMV
Human CMV is a persistent herpes virus that is present in
approximately 50% of the adult population and may
reach 90% in the elderly in Europe. CMV infection in
immunocompetent individuals is normally asympto-
matic, but can be a major cause of morbidity in immuno-
suppressed individuals and susceptible neonates. The
control of CMV infection by the immune system is then of
major importance to delay/decrease its effect on the indi-
vidual's health [14]. There are reports where it appears
that CMV infection could alter the composition of the dif-
ferent T cell subsets, showing an increased number of
CD8+CD57+ subset in CMV-seropositive individuals. In
earlier studies, it has been reported that CMV seropositiv-
ity is associated with an increased number of both CD4+
and CD8+ CD28-negative cells. Independently, this phe-
notype has also been associated with age. However it may
in fact be primarily associated with CMV status and only
secondarily with age, linking the increased frequency of
CMV infection to age. But both age and CMV status influ-
ence the number of CD8+ cells and the expression of
CD45RA and CD28 [14-17].
One of the immunodominant viral antigens recognized
by CMV specific CD8+ T cells, at least in HLA-A2+ donors,
is derived from the 65-KDa phosphoprotein (pp65).
From this protein the immunodominant epitope pre-
sented by HLA-A*0201 has been used to investigate the
frequency of CD8+ cells against CMV. The OCTO and
NONA samples have been studied using MHC/peptide
tetramers and preliminary data revealed that a large
number of CD8 and CD28-negative cells where specific
for the pp65 antigen. It has become evident that a subset
of CD8+ cells, generally of the memory phenotype,
expresses inhibitory NK receptors which can block CTL
effector function. Together with the well-known phenom-
enon of CD8 clonal expansions presented in the elderly,
these findings imply a co-dominant role of CMV as a
cause for a compromised immunity in old age. Mainly,
two different approaches have tried to pinpoint the influ-
ence of CMV on the ageing of the human immune system.
The first was the development of tetramer technology to
directly identify T cells carrying receptors for single pep-
tide epitopes; and the second, the development of longi-
tudinal studies of naturally ageing populations.
Importantly, this study also indicated that the risk pheno-
type was independent of the individuals' health status at
that particular time. [4-6,18-20].
CD8
The clonal expansion of CMV-specific CD8+ T cells which
accumulate progressively with age resemble CD8+ T cells
that are driven to the end-stage of replicative senescence in
cell culture in response to repeated rounds of antigen-
driven proliferation, and which may also be found in can-
cer patients (21). Senescent CD8+ T cell cultures show
downregulation of CD28 expression and shortened tel-
omeres. In fact, the oligoclonally expanded cells within
the CD8+CD28- T cell population generally have shorter
telomeres than the CD28- subset as a whole, suggesting
extensive proliferation, presumably in response to chronic
antigenic exposure [22]. The majority of the CD8+ T cells
specific for CMV in the elderly is probably dysfunctional
at least in terms of IFN-γ production (but this may also be
a property of end-stage differentiation effector CTL). A
minority of CMV-specific CD45RA+ reverted cells found
in the elderly, however, constitute a different population:
one which remains capable of proliferation and interferon
secretion, like the majority of CD28- cells with the same
CMV specificity in young donors. Antigen-specific dys-
functional T cells have been also described in EBV, HIV
and HCV infected patients, melanoma and renal carci-
noma patients and in rheumatoid arthritis patients. In all
these conditions, chronic antigenic stress may result in the
accumulation of clonal expansions of dysfunctional
"anergic" T cells partly due to apoptosis resistance. This is
still matter of debate but this mechanism might contrib-
ute to the increased CD8+ antigen-specific T cell number
under conditions of chronic antigen stresses. This could
also be true in the young population subjected to persist-
ent antigenic stresses, particularly cancer patients in devel-
oped nations and parasite-infected patients in less-
Table 2: Characteristics of the immune risk phenotype
CD4:8 ratio < 1
poor T cell proliferative responses to mitogens
increased CD8+CD28-negative and CD8+CD57+ cells
low B cells count
CMV-seropositivity
clonal expansions of CD8 cells carrying receptors for CMV
high proportion of dysfunctional cells amongst the CMV-specific CD8 cellsPage 3 of 6
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exhaustion due to pathogen or tumor escape from the
immune system [21-25].
CD28
CD28 is an important receptor affecting both T cell activa-
tion and susceptibility to apoptosis, the expression of
which is well-documented as being decreased in aged
individuals. CD28 costimulation is required for T cell acti-
vation and to prevent anergy and to activate telomerase.
Together with telomere shortening, loss of CD28, espe-
cially together with loss of CD27, can be taken as a marker
for T cell replicative senescence and/or end-stage differen-
tiation [22]. Both the OCTO/NONA studies showed a sig-
nificant decrease of CD28 expression by CD8 cells of old
compared to middle-aged individuals. This was particu-
larly marked in old individuals with an inverted CD4/8
ratio of <1, who are most at risk for incipient mortality
[25]. Stimulation of T cells via T cell receptor and CD28
leads to the activation of a myriad of signalling pathways
that ultimately induce the translocation of transcription
factors such as NF-AT and NF-kB to the nucleus initiating
IL-2 production, or other effector functions.
Clonal expansion and effector function are then possible.
Most investigators agree that the CD8+CD28- population
increases with age and CMV seropositivity. Nevertheless,
these cells are still able to respond to certain stimuli such
as IL-15 which preferentially extends CD8+ memory cell
lifespan. The recent discovery of membrane rafts may help
to understand why cells respond to some stimuli and not
to others. Membrane rafts are specialized membrane
microdomains where the signalling platform is formed.
Surprisingly, CD8+ cells possess a pre-assembled signalo-
some that might account for their ability to maintain
CD28 signalling (via Akt phosphorylation) despite CD28
downregulation to apparently minimal or zero levels [26].
The use of in vitro aged T cell clones (TCC) allows accurate
discrimination between CD28-low and CD28-negative
cells. In vivo, it may also be the case that CMV-specific
CD8+ expanded T cells still retain some CD28 on the sur-
face. Our preliminary data using TCC derived from young,
OCTO and centenarian donors show that Akt activation
was inducible although these cells were classified in regu-
lar flow cytometry as CD28-negative. The maintenance of
CD28 signalling can be attributed to the lateral mobility
of membrane rafts which can concentrate the remaining
CD28 molecules to the site of stimulation. Expression lev-
els of CD28 can still be taken as a marker of immune
senescence and cell replication. However, CD28 downreg-
ulation alone is not a marker for loss of functions since
CD28 localization is as important as its expression level
[27]. Membrane rafts are not only crucial for T cell activa-
tion but also for other processes such as apoptosis com-
mitment. The Fas-dependent pathway was shown to
involve death-inducing signalling complex (DISC) forma-
tion in membrane rafts [28]. Since changes in membrane
raft properties have been found in CD4+ T cells from eld-
erly individuals there is the possibility that CD8+ rafts
also undergo changes due to repeated rounds of stimula-
tion. These changes can lead to a differential capacity of
DISC formation and could account for the resistance to
apoptosis thought to play a role in the accumulation of
CMV-specific CD8+ cells.
KIR
Antiviral CD8+ T cell responses are regulated by killer cell
inhibitory receptors, which can be divided into two struc-
tural types, killer immunoglobulin-like receptors (KIR)
and killer cell lectin-like receptor (KLR) belonging to the
C-type lectin family. The inhibitory receptor KLRG1 is
expressed on 50% of CD8+ cells in young donors,
whereas in the elderly the percentage rises to 80%. A dis-
tinguishing characteristic of the majority of KLRG1+ cells
is that they are unable to undergo further clonal expan-
sion. Furthermore, about 90% of CMV tetramer-positive
CD8+ T cells in the elderly are also positive for KLRG1
compared to 70% in the young. Thus, persistent infection
with CMV may lead to a gradual increase in the already
high number of KLRG1+CD8+ cells during ageing. In the
absence of TCR engagement, expression of KIR on non-
self-reactive CD8+ cells is lowered to levels that no longer
inhibit T cell function, suggesting that KIR expression is
sustained by continuous encounter with antigens [29]. It
also been seen, using intracellular cytokine staining, that
the proportion of cells producing IFN-γ after specific anti-
gen stimulation is higher in KLRG1+ CD8 cells regardless
of age. However, CD8+ cells from old donors seem to pro-
duce less IFN-γ than young donors, regardless of KLRG1
expression. Nevertheless, CD8+KLRG-1+ cells are signifi-
cantly more resistant to apoptosis. Recently, it was shown
that the KIR2DL2 receptor was associated to membrane
rafts and inhibited immune synapse formation and cellu-
lar activation in CD4+ T cells [21,23-25,29]. Further stud-
ies in CD8+ T cells are needed to test the hypothesis that
inhibitory receptors are involved in CD8+ T cell anergy.
Accumulation of dysfunctional cells
In addition to the persistent antigenic stimulus of the
latent virus, age-associated dysregulation of apoptosis
could account for the accumulation of dysfunctional
CD8+ cells. In contrast, CD4+ cells seem to become
increasingly susceptible to apoptosis with age, at least in
vitro [20]. Increased resistance of CD8+ cells and
increased susceptibility of CD4+ cells to apoptosis could
help to explain the inverted CD4:8 ratio in the elderly,
part of the IRP. In addition, telomerase activity, which
compensates for the telomere attrition associated with the
massive clonal expansion of virus-specific CD8+T cells in
the blood and also in the lymphoid tissue, is progressivelyPage 4 of 6
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antigen-driven proliferation [30]. In IRP elderly, dysfunc-
tional CMV-specific CD8+ T cells may accumulate because
of compromised apoptotic pathways. Homeostasis is
thought to maintain a constant number of T cells in the
periphery by T cell proliferation, accumulation, death or
renewal. Although thymic output is maintained in elderly
individuals, at least to some degree, the difficulty in iden-
tifying naïve cells in the very elderly suggests that this may
contribute to increased susceptibility to infectious disease.
Hence, as most of the old individuals are CMV-positive,
together with thymic involution, this might result in a
marked shrinkage of the T cell repertoire for novel anti-
gens. These data are consistent with the hypothesis that in
the elderly the "immunological space" is occupied by dys-
functional anergic clonally expanded T cells specific for
very few epitopes. This situation would leave the individ-
ual likely to be more prone to infectious disease and pos-
sibly also cancer, and may contribute to explaining the
greater incidence of those diseases in elderly [5-
7,9,25,31,32]
Future perspectives
There remain many uncertainties still to clarify such as: a)
Is there an immunogenetic component influencing the
IRP phenotype that might explain the different degree of
CMV clonal expansion vs non-IRP phenotype? b) May
this difference depend on social or/and environmental
factors? c) Might the genetic or environmental component
affect the degree of clonal expansion of CMV in IRP indi-
viduals? d) What can be the main cause of death in IRP
group vs non-IRP? e) Can IRP selection be predictive in
young as well as in old individuals? f) Is it possible to
revert/prevent accumulation of CMV-specific cells?
Human studies will require knowledge at least of the
immunological history of the individual to be able to
answer the above questions. Unfortunately, this is logisti-
cally and financially problematic, but it is to be hoped
that Europe-wide studies may be established in he near
future to explore these issues. The answers to all these
questions will have practical implications and provide a
route to novel interventions to understand and improve
overall health and well-being in old age.
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